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In collating and synthesizing several data sources on cannabis exposure, Manthey and colleagues have elegantly compiled a foundational
resource for subsequent epidemiological studies on cannabis use [1].
The study includes an impressive body of evidence on cannabis use
prevalence (in the month and year prior to interview), high risk cannabis use (daily or near daily), tetrahydrocannabinol (THC—the principal
psychoactive constituent of cannabis) concentration in European cannabis herb and processed resin (cannabis concentrates), and treatment
demand for Cannabis Use Disorder (CUD). All four domains studied
show a modest to dramatic increases across 2010-2019.
The authors found large increases in cannabis use prevalence of
25% to 82% in age strata 15-24 years and 55-64 years, respectively.
High risk (almost) daily use also rose in many nations and by 600%,
48% and 45% in Portugal, Spain, and France respectively. The concentration of THC in cannabis herb and resin rose 54% and 217% and in
nations such as France, Sweden and Luxembourg THC concentrations
in cannabis resin rose 2.3-2.5% annually. Continent-wide 30%
increases were noted in admissions for CUD treatment including
increases of 700%, 260%, 210% and 170% in Luxembourg, Malta, Sweden, and France respectively. These data contrast recent estimates
from GBD which are generally lower and remarkably constant. This
study therefore adds to others challenging GBD CUD estimates (Manthey References 67, 68 and 81).
The authors correctly list several complications of cannabis
including CUD, mental illness, cognitive impairment, motor vehicle
accidents, chest disease and testicular cancer. They astutely list doseresponse effects for CUD, psychoses and anxiety. Dose-response
effects have also been also noted for testicular cancer [2] where cannabis exposure dramatically accelerates the preclinical oncogenic
phase from several decades to less than about 14 years [2]. A
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particular concern is the abrupt threshold effect in dose-response
relationships of many toxic cannabinoid effects with sharp jumps in
incidence for many malignant and congenital genotoxic outcomes at
higher dose levels [2 7].
Cannabis exposure was recently implicated epidemiologically in
cancers of the breast, thyroid, liver, pancreas and acute myeloid leukaemia [7] as well as in the major childhood cancer acute lymphoid
leukaemia [3] and as a primary driver of the 50% rise in total paediatric cancers in the USA 1975-2017 [6]. Cannabis exposure was also
recently implicated in all ﬁve longitudinally tracked chromosomal
birth defects in USA: trisomy 21, 18 and 13, and Turners and DiGeorge
syndromes [7]. Similar studies have conﬁrmed a direct relationship of
cannabis to dozens of congenital anomalies in Australia and Canada
[7]. Importantly, given this mounting evidence that cannabinoids are
genotoxic [7] and have epigenetic effects which are generationally
transmissible [8], there is a major concern that much of this increased
cannabinoid exposure is concentrated in adults of reproductive age.
The overall picture emerging from this study is a very concerning
simultaneous quadruple conﬂuence of rising prevalence of use, rising
intensity of use, rising THC potency and rising requests for CUD treatment, all likely interacting multiplicatively. These data are particularly
signiﬁcant in the context of increasing international concern relating to
the generationally transmissible effects of genotoxicity and epigenotoxicity from cannabinoids [7,9,10]. Moreover, data indicate that cannabis
liberalisation is associated with a simultaneous intensiﬁcation of several
of these trends (see Figures 1-4 from Manthey and colleagues [1]). These
data are therefore important to consider when planning further liberalisation of cannabinoids, their increasing penetration into the community
food chain, impacts on child mental health [4] and cellular aging [8,9].
A primary limitation of the current study concerns the data gaps for
some of the studied variables. This is inevitable given the multi-jurisdictional nature of data collection across Europe. It also necessitates some
form of data completion procedure. The option chosen by the authors
is limited linear interpolation which is a reasonable choice here. It is
also highly important that measures from some high use nations such
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as Belgium, Luxembourg and France are incomplete, particularly indices
relating to high intensity daily consumption. Additionally, data on concentration of cannabinoids other than THC is not available which would
be highly relevant to the current context.
These major gaps in the data constitute important areas for future
research in this very important dataset. Given the above-mentioned
concerns relating to generationally transmissible impacts of cannabinoids, burning questions which urgently require addressing concern
the epidemiological effects of high level cannabinoid exposure, and the
effects of the various cannabinoids. Moreover, since frequency, intensity
and concentration data are concurrent and often simultaneous across
space and time, their multiplicative and interactive effects also need to
be assessed. The data also lend themselves to spatiotemporal investigation and application of the techniques for formal causal inference to
eventually support formulation of rational drug policies.
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